Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Konrad Rejdak

Showing results (1-10 of 186) with videos related to

Pageof 19
Sort By:
Journal of Neural Transmission (Vienna, Austria : 1996)|October 22, 2016
Anti-MAG autoantibodies are increased in Parkinson's disease but not in atypical parkinsonismEwa Papuć, Konrad Rejdak
European Journal of Neurology|July 7, 2021
Cladribine suppresses disease activity in neuromyelitis optica spectrum disorder: a 2-year follow-up studyKonrad Rejdak, Ewa Papuć
Frontiers in Neuroscience|February 27, 2023
Late neurological consequences of SARS-CoV-2 infection: New challenges for the neurologistAgnieszka Korchut, Konrad Rejdak
Annals of Agricultural and Environmental Medicine : AAEM|July 9, 2014
The role of neurostimulation in the treatment of neuropathic painEwa Papuć, Konrad Rejdak
Current Neuropharmacology|July 30, 2021
Fluvoxamine and Amantadine: Central Nervous System Acting Drugs Repositioned for COVID-19 as Early InterventionKonrad Rejdak, Paweł Grieb
Frontiers in Aging Neuroscience|August 15, 2020
Increased Cerebrospinal Fluid S100B and NSE Reflect Neuronal and Glial Damage in Parkinson's DiseaseEwa Papuć, Konrad Rejdak
Frontiers in Aging Neuroscience|June 2, 2020
Increased CSF NFL in Non-demented Parkinson's Disease Subjects Reflects Early White Matter DamageEwa Papuć, Konrad Rejdak
Multiple Sclerosis and Related Disorders|May 11, 2020
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairmentKonrad Rejdak, Paweł Grieb
Archives of Medical Science : AMS|March 20, 2020
The role of myelin damage in Alzheimer's disease pathologyEwa Papuć, Konrad Rejdak
Folia Neuropathologica|July 21, 2021
Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?Paweł Grieb, Konrad Rejdak
Pageof 19

Showing results (1-10 of 186) with videos related to

Sort By:
Pageof 19
Journal of Neural Transmission (Vienna, Austria : 1996)|October 22, 2016
Anti-MAG autoantibodies are increased in Parkinson's disease but not in atypical parkinsonismEwa Papuć, Konrad Rejdak
European Journal of Neurology|July 7, 2021
Cladribine suppresses disease activity in neuromyelitis optica spectrum disorder: a 2-year follow-up studyKonrad Rejdak, Ewa Papuć
Frontiers in Neuroscience|February 27, 2023
Late neurological consequences of SARS-CoV-2 infection: New challenges for the neurologistAgnieszka Korchut, Konrad Rejdak
Annals of Agricultural and Environmental Medicine : AAEM|July 9, 2014
The role of neurostimulation in the treatment of neuropathic painEwa Papuć, Konrad Rejdak
Current Neuropharmacology|July 30, 2021
Fluvoxamine and Amantadine: Central Nervous System Acting Drugs Repositioned for COVID-19 as Early InterventionKonrad Rejdak, Paweł Grieb
Frontiers in Aging Neuroscience|August 15, 2020
Increased Cerebrospinal Fluid S100B and NSE Reflect Neuronal and Glial Damage in Parkinson's DiseaseEwa Papuć, Konrad Rejdak
Frontiers in Aging Neuroscience|June 2, 2020
Increased CSF NFL in Non-demented Parkinson's Disease Subjects Reflects Early White Matter DamageEwa Papuć, Konrad Rejdak
Multiple Sclerosis and Related Disorders|May 11, 2020
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairmentKonrad Rejdak, Paweł Grieb
Archives of Medical Science : AMS|March 20, 2020
The role of myelin damage in Alzheimer's disease pathologyEwa Papuć, Konrad Rejdak
Folia Neuropathologica|July 21, 2021
Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?Paweł Grieb, Konrad Rejdak
Pageof 19